Edition:
United States

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

27.08USD
5 Dec 2016
Change (% chg)

$0.81 (+3.08%)
Prev Close
$26.27
Open
$26.71
Day's High
$27.74
Day's Low
$26.28
Volume
108,035
Avg. Vol
87,456
52-wk High
$34.89
52-wk Low
$14.85

MGNX.OQ

Chart for MGNX.OQ

About

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer,... (more)

Overall

Beta: --
Market Cap(Mil.): $957.29
Shares Outstanding(Mil.): 34.84
Dividend: --
Yield (%): --

Financials

  MGNX.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.56 -- --
ROI: -15.36 -1.09 14.95
ROE: -16.33 -2.39 16.29

BRIEF-Macrogenics files for potential mixed shelf offering

* Files for potential mixed shelf offering; size not disclosed - SEC filing Source text: [http://bit.ly/2eBbLcf] Further company coverage:

Nov 02 2016

BRIEF-Macrogenics Qtrly loss per share $0.97

* Q3 earnings per share view $-0.80, revenue view $12.5 million -- Thomson Reuters I/B/E/S

Nov 02 2016

BRIEF-Takeda and Macrogenics announce conclusion of MGD010 license and option agreement

* Takeda and Macrogenics announce the conclusion of their MGD010 license and option agreement

Sep 12 2016

BRIEF-Macrogenics says on track for three new IND submissions in 2016-2017

* Macrogenics provides update on corporate progress and second quarter 2016 financial results

Aug 03 2016

BRIEF-Macrogenics presents data from phase 1 study of MGD010

* Macrogenics presents data from phase 1 study of mgd010 at annual european congress of rheumatology (eular 2016)

Jun 10 2016

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF222.10 +1.50
Roche Holding Ltd. (RO.S) CHF226.00 +1.40
Amgen, Inc. (AMGN.OQ) $145.29 +1.28
Xencor Inc (XNCR.OQ) $26.78 +0.67

Earnings vs. Estimates